TQD, which was in all likelihood caused by transporter saturation at high TQD doses. Acceptable safety and tolerability as well as dose-linear increases in plasma exposure support the future use of TQD at doses up to 8 mg/kg to inhibit Pgp at the human blood-brain barrier.
Introduction
The ATP-binding cassette transporter P-glycoprotein (Pgp, ABCB1) is expressed in the luminal membranes of the small intestine and blood-brain barrier (BBB) or in the apical membranes of excretory cells such as hepatocytes and kidney proximal tubule epithelia [1] . Pgp actively transports a wide range of structurally diverse, mostly lipophilic, compounds against concentration gradients and thereby exerts a considerable impact on drug absorption, distribution and excretion. A multitude of studies have linked increased expression of Pgp in tumors to impaired chemotherapy response and lower patient survival [2] . In addition, disease-related increases in activity of Pgp at the BBB probably contribute to therapy refractoriness in neurological diseases like epilepsy and 13 depression by impeding the accumulation of therapeutically effective drug concentrations in tissue targeted for treatment [3] .
For over 2 decades, efforts to inhibit Pgp to overcome multidrug resistance in cancer have been made [4] [5] [6] . In early clinical trials, first-generation Pgp inhibitors, such as verapamil and cyclosporine A, were used, which were toxic at concentrations needed to inhibit Pgp. Second-generation Pgp inhibitors such as valspodar (PSC 833) and biricodar (VX-710) were more potent and less toxic than firstgeneration Pgp inhibitors. Unfortunately, drug-drug interactions, involving cytochrome P450 3A4 (CYP3A4) inhibition, were leading to increased systemic exposure, and hence, to elevated toxicity of chemotherapeutic drugs [6] . These limitations led to the development of more potent and specific third-generation Pgp inhibitors including tariquidar (XR9576, TQD), elacridar (GF120918), zosuquidar (LY335979), laniquidar (R101933) and ONT-093 [7] [8] [9] [10] [11] .
Until now, clinical pharmacokinetic (PK) data of TQD are available for doses administered intravenously up to 2 mg/kg body weight (BW). Linear dose-dependent increases in the area under the curve (AUC) and the peak serum TQD concentration (C max ) between 0.1 and 2 mg/ kg were reported [4, 7] . The 2-mg/kg dose has been chosen for clinical trials with TQD in cancer patients as this dose was shown to fully inhibit Pgp-mediated rhodamine 123 efflux from CD56-positive lymphocytes, which was used as a surrogate marker of Pgp inhibition occurring in vivo [4, 7] . However, in contrast to the inhibition of Pgpmediated rhodamine 123 efflux from CD56-positive lymphocytes, the half-maximum effect concentration for functional inhibition of Pgp at the human BBB was found to be several times higher (669 vs. 33 nmol/l), suggesting that Pgp at the BBB is more resistant to inhibition than Pgp in peripheral organs [7, 12] . Consequently, TQD doses higher than 2 mg/kg will be needed to effectively block Pgp at the human BBB.
Higher doses of TQD (up to 8 mg/kg) were recently investigated in vivo in clinical positron emission tomography (PET) imaging studies with Pgp substrate radiotracers [12, 13] . Pgp substrate penetration into the brain, as a measure of pharmacodynamic response, was found to increase as a function of administered TQD dose [12, 13] . The present study describes concomitant PK of TQD administered at doses between 4 and 8 mg/kg, which is considered being mandatory for further pharmacodynamic studies with high doses of this compound. Since the stability of TQD in human plasma is unknown, a separate in vitro experiment was performed to investigate stability over time at different storage conditions.
Methods

Study Population
The present study was conducted at the Department of Clinical Pharmacology, Medical University of Vienna. The study was approved by the local Independent Ethics Committee and the National Competent Authority and performed in accordance with guidelines established by the Declaration of Helsinki and its amendments. All subjects were given a detailed verbal and written description of the study, and their written consent was obtained prior to enrolment into the study.
Healthy volunteers underwent a normal physical examination with no clinical significant findings in vital signs, laboratory values and electrocardiogram (ECG) results as considered by the investigator. Subjects were not enrolled in the study if they had participated in a clinical study with an investigational drug 1 month or had taken any medication within 2 weeks prior to the study day. Subjects who had donated blood or plasma within 3 months prior to the first visit, as well as those with a significant medical history and a history of drug or alcohol abuse, were also excluded.
Fifteen young male subjects were randomized into three dose groups. Data were acquired aligned with a previously published PET study [12] . Furthermore, data from a pilot study in which subjects had received 2 mg/kg BW TQD are shown for comparison [14] .
Study Design and Treatment
The study was designed as a single-dose escalation study with administration of TQD at 4, 6 and 8 mg/kg BW. 10-ml vials of TQD for intravenous infusion containing 7.5 mg/ml of TQD-free base in 20% ethanol/80% propylene glycol were provided by AzaTrius Pharmaceuticals Pvt. Ltd. (London, UK). Following a recently described procedure [12] , TQD was freshly diluted in 5% (w/v) aqueous dextrose solution to a fixed concentration of 0.6 mg/ml and infused intravenously at a rate of 375 ml/h until achieving the target dose. This procedure differs from the 2-mg/ kg dose group in which a fixed infusion duration of 0.5 h was applied [14] . Blood samples were collected in tubes containing sodium heparin as an anticoagulant before administration of the dose, at time points of 25, 50 and 75% of the infusion duration, at the end of the infusion, and at 5, 10, 20, 30, 60, 120 and 1,440 min after the end of the infusion. Immediately after blood drawing, samples were stored on crashed ice until centrifugation, after which plasma was frozen at -20°C within 30 min. At the end of each study day, the samples were transferred to a -80°C freezer.
Safety and Tolerability
All subjects were confined to the clinical ward under continuous medical observation until 24 h after the end of the TQD infusion. Clinical safety monitoring included repeated recording of blood pressure, heart rate and ECG data for the first 24 h after dosing, clinical chemistry, coagulation and hematology, assessments of adverse events (AEs) and their follow-up completion. Final visits for physical examination, vital sign and AE check as well as for blood and urine analysis were scheduled within 1 week after the study day.
Plasma PK Analysis
The concentrations of TQD in plasma were measured with high-performance liquid chromatography (HPLC) mass spectrometry using a Dionex UltiMate 3000 system (Dionex Corp., Sunnyvale, Calif., USA) connected with an API 4000 triplequadrupole mass spectrometer (Applied Biosystems, Concord, Ont., Canada). After addition of 200 μl of methanol to 100 μl of plasma, the samples were centrifuged (5,000 g for 5 min at 4°C) and 80 μl of the clear supernatant was injected onto the HPLC column. Separation of TQD was carried out at 35°C using a Hypersil BDS-C18 column (5 μm, 250 × 4.6 mm i.d.; Thermo Fisher Scientific, Inc., Waltham, Mass., USA) preceded by a Hypersil BDS-C18 pre-column (5 μm, 10 × 4.6 mm i.d.). The mobile phase consisted of a continuous linear gradient, mixed from 10 mmol/l aqueous ammonium acetate/acetic acid buffer, pH 5.0, and methanol. Linear calibration curves were generated by spiking drug-free plasma with standard solutions of TQD (final concentrations ranging from 0.005 to 5 μg/ml). The lower limit of detection of TQD was 3 ng/ml and the lower limit of quantification was 5 ng/ml.
PK Calculations and Statistical Analysis
C max and time at maximal concentration were recorded directly from experimental observations. PK parameters AUC from start until 24 h after the end of the infusion (AUC 0-n ), volume of distribution at steady state (V SS ), clearance and terminal elimination half-life time were calculated by using the Kinetica 2000 software package, version 3.0 (InnaPhase, Philadelphia, Pa., USA). The relationship between the PK variables AUC 0-n and V SS and the administered dose was determined using linear regression. We included the data from our pilot study [14] for linear fitting to consistently connect our new high-dose PK data with those from the literature. Origin, version 7 (OriginLab Corporation, Northampton, Mass., USA), was used for linear regression and statistical computations. The level of significance was set at p < 0.05.
Stability Study
The stability of TQD in plasma was examined at three different concentrations (0.1, 0.5 and 2.0 μg/ml TQD). Each stock solution was subdivided into 16 separate aliquots. The first 4 aliquots were immediately analyzed by HPLC. The TQD concentrations obtained from this quantification were considered as baseline concentrations for subsequent long-term quantifications. The 12 remaining aliquots were stored for 24 h, 1 month and 3 months, respectively, at 4 different temperature levels, i.e. room temperature (RT), 4°C, -20°C and -80°C. Subsequently, these aliquots were used for measuring TQD concentrations after the specified time intervals. The default criterion for TQD stability was set at 95%.
Results
Demographics
In the present study, all participants were males, 14 Caucasians and 1 Hispanic. The mean age and weight ± standard deviation (SD) for the 4-, 6-and 8-mg/kg dose groups were 36.3 ± 11.2, 29.9 ± 8.3 and 31.4 ± 6.0 years and 84.6 ± 7.8, 88.4 ± 13.2 and 74.4 ± 8.4 kg, respectively.
Safety and Tolerability
The study medication was generally well tolerated and no serious or severe AEs were observed. Overall, 4 cases of hematoma and 1 case of phlebitis due to cannulation as well as 5 cases of metallic taste in the mouth occurred. Other adverse drug effects to TQD were vertigo (n = 2), bradycardia (n = 1) and headache (n = 1). Heart rate, blood pressure as well as ECG did not significantly change during and after TQD administration. No subject had any significant change in blood chemistries (including electrolytes, liver and renal function tests), complete blood count and coagulation over the whole study period. No volunteer discontinued the study prematurely. In the case of the last subject, for safety reasons, the infusion was stopped 20 min before the scheduled end due to moderate orthostatic hypotension and vertigo. This AE did not influence any other study-related procedures.
Pharmacokinetics
The clinical part of the study was completed within 1 month. Plasma samples were stored at -80°C for 4-5 months until analysis. Mean plasma concentration-time curves of TQD are depicted in figure 1 . In all plasma samples, the concentration of possible metabolites was below the detection limit. Mean infusion duration was 1.50 ± 0.14 h for the 4-mg/kg, 2.35 ± 0.35 h for the 6-mg/ kg and 2.58 ± 0.22 h for the 8-mg/kg dose group. For the respective dose groups, the mean administered TQD dose was 338 ± 31, 530 ± 79 and 580 ± 50 mg. Individual PK parameters are presented in table 1. There was a statistically significant positive correlation between injected dose and the PK parameters AUC 0-n (coefficient of correlation r = 0.8981, p < 0.0001) ( fig. 2 ) and V SS (r = 0.7129, p = 0.0004) ( fig. 3 ).
Stability
In table 2, the results of the stability study are shown with TQD concentration values displayed as absolute and percent values relative to baseline concentrations. Applying the prespecified default criterion for TQD stability (i.e. 95%), TQD was stable for 24 h at RT, 4°C, -20°C and -80°C, respectively. Any longer storage resulted in pronounced degradation, even at -80°C.
Discussion
In the present study, we describe for the first time the PK of the potent and selective third-generation Pgp inhibitor TQD in healthy volunteers after intravenous ad-ministration of doses which were up to 4 times higher than those previously used in clinical trials with this drug in cancer patients (2 mg/kg) [4] . TQD doses higher than 2 mg/kg are required to achieve effective inhibition of Pgp at the human BBB [12, 13] , which could find future therapeutic application to enhance brain penetration of anticancer or antiepileptic drugs [15, 16] . For instance, it has been shown that brain distribution of several tyrosine kinase inhibitors (e.g., gefitinib, sorafenib, dasatinib, sunitinib, lapatinib) is restricted by transporter-mediated efflux transport at the BBB [15] , suggesting that their efficacy might be improved when coadministered with a Pgp modulator. A previously conducted clinical PET study, in which brain penetration of the radiolabeled model Pgp substrate (R)-[ 11 C]verapamil was assessed in healthy subjects as a surrogate marker of cerebral Pgp activity, had shown that at a TQD dose of 8 mg/kg, complete inhibition of Pgp at the human BBB was achieved as reflected by a plateau in the concentration-response curve of TQD [12] . For the 2-mg/kg TQD dose, (R)-[ 11 C]verapamil brain distribution was only 1.25-fold enhanced as compared with baseline scans without TQD administration, whereas for the 8-mg/kg TQD dose, a 3-fold increase in (R)-[ 11 C]verapamil brain distribution was observed [12] . Choo and colleagues [17] reported that the halfmaximum effect dose of TQD to enhance the brain-toplasma ratio of the Pgp substrate loperamide in mice was approximately 4 times higher than the half-maximum effect dose for increasing the testis-to-plasma ratio suggesting that cerebral Pgp is less amenable to inhibition as compared with Pgp in peripheral organs. Based on these data, it can be assumed that in our study, Pgp was fully inhibited at the highest employed TQD dose (8 mg/kg), not only at the BBB but also in peripheral organs (e.g., liver, kidneys). There is evidence from previous studies that apart from being a potent inhibitor of Pgp, TQD is also transported at low concentrations by Pgp and breast cancer resistance protein [18] [19] [20] . Thus, this study provided us with the unique opportunity to assess the PK of a Pgp/breast cancer resistance protein substrate drug after intravenous administration over a dose range which most likely induced full inhibition of Pgp in all organs. As expected, this clearly resulted in non-linearity of TQD PK, i.e. the V SS increased as a function of administered dose ( fig. 3 ). V SS was up to 3 times higher for the 8-mg/kg TQD dose as compared with the 2-mg/kg dose. This could be due to increasing inhibition of Pgp in different tissues protected by Pgp with increasing TQD doses leading to enhanced distribution of the Pgp substrate TQD from plasma into these tissues. This assumption is supported by findings from a previous preclinical study, in which it was shown that the brain-to-plasma concentration ratio of TQD in rats (a measure of drug distribution to brain) was approximately 3 times higher after administration of a high dose of TQD (15 mg/kg) as compared with a microdose (0.002 mg/kg) [18] . Similar results were recently reported for the Pgp modulator elacridar, for which brain distribution in rats or mice was found to be dependent of elacridar plasma concentration levels [21] [22] [23] , suggesting that at high plasma concentrations, Pgp at the BBB was inhibited leading to increased brain exposure to elacridar. The dose dependency of the V SS of TQD has not been reported in a previous dose escalation study up to a maximum dose of 2 mg/kg [7] .
In our study, TQD plasma concentration-time profiles were characterized by a fast initial and subsequent flat- tened increase until the end of the infusion ( fig. 1 ). This observation might also be related to the ability of TQD to distribute extensively from the vascular system into tissues, possibly by inhibition of transporter-mediated efflux processes at higher concentrations. After the end of the infusion, a rapid decrease in plasma TQD concentrations was followed by a secondary peaking within the first few hours ( fig. 1) , which might be a consequence of enterohepatic circulation of TQD. Concentrations of TQD in plasma within individual dose groups were found to be quite variable despite traditional dose calculation based on mg/kg BW and parenteral administration (table 1) . This has also been observed in previous studies [12, 14] . Such a high variability in plasma concentration has also been described for other Pgp inhibitors, such as elacridar, [10, 24] valspodar [25] and zosuquidar [26] , and might be caused by distribution into deep compartments such as the muscle, kidney, liver and pancreas and/or variability in oral absorption rate due to the high lipophilicity of these compounds. Interestingly, we could not detect any metabolites in plasma samples indicating that TQD biotransformation in humans is negligible.
Despite the pronounced dose dependency of V SS ( fig.  3) , plasma exposure to TQD, i.e. AUC 0-n , was found to largely increase linearly with increasing doses over the dose range from 2 to 8 mg/kg ( fig. 2 ). This stands in contrast with the Pgp inhibitors zosuquidar and laniquidar, for which greater than proportional increases in AUC had been found with increasing dose [8, 9] .
Importantly, TQD at doses up to 8 mg/kg BW was generally well tolerated with no particular safety concerns occurring in our study. Although the majority of subjects reported at least 1 AE, no serious or severe AEs were reported. It cannot be excluded that the most common AE, metallic taste in the mouth, was related to propylene glycol used as co-solvent for the TQD injection solution [13] . In 1 case, shortly before the scheduled end of the TQD infusion, the administration was prematurely stopped as the subject reported orthostatic hypotension and vertigo. Both symptoms receded rapidly after de-challenging the infusion. Taken together, no dose-limiting toxicities at C max values ranging from 1.05 to 2.03 mg/l were seen. The good tolerability of TQD at doses up to 8 mg/kg is important as it supports the future clinical use of TQD at doses >2 mg/kg for inhibition of Pgp at the BBB. However, clearly, for such a future application, an oral administration mode would be preferred over the currently employed intravenous route. A particular disadvantage of intravenous dosing is the long infusion duration (up to 3 h for the 8-mg/kg dose), which, for safety reasons, was necessary to keep the percentage of the co-solvent in the infusion solution at <14% to avoid hemolysis as side effect.
We describe, for the first time, the stability of TQD in plasma under different controlled storage conditions (table 2). TQD was found to be stable for 24 h at RT, 4°C, -20°C and -80°C, respectively. However, after 1 month of storage at RT or at 4°C, the concentrations had degraded to only approximately 10% of the original concentration. More important, even when stored at -20°C, TQD concentration after 1 month decreased to 74-78% and, at -80°C, to 78-82% of the original values. No concentration dependency was seen for the degradation rate of TQD. It is noteworthy that the instability of TQD in plasma was not mentioned in a previously published report which examined the PK of TQD in human subjects [7] .
The pronounced degradation of TQD in plasma over time resulting in lower concentrations than actually present at the time of sampling might be considered as most important limitation of the present study. However, as both sample collection and analysis of plasma samples were performed within relatively short time frames, total storage times of individual samples until analysis were overall similar, justifying a relative comparison of PK parameters between different dose groups. This is further supported by our observation that degradation of TQD in plasma appeared to be independent of concentration (table 2). As second limitation, the data of the 4-, 6-and 8-mg/kg dose groups can only partially be compared with the previously described 2-mg/kg dose group [14] due to [14] . modification in the administration scheme. The approach of using a fixed stock solution for TQD dose escalation was used to avoid excess propylene glycol concentrations of the infusion solution for the high TQD dose groups [13] . This change in administration scheme leads to different infusion durations and may therefore hamper the comparability of C max values among dose groups.
In conclusion, our results extend previous findings by showing linear plasma exposure to TQD administered intravenously at doses up to 8 mg/kg BW [4] . High-dose administration of TQD seems acceptable from the safety point of view which is a prerequisite for future use of this drug to enhance brain penetration of Pgp substrate drugs. Due to the instability of TQD in plasma, analytics should be performed as fast as possible. Storage times of plasma samples containing TQD should be accurately recorded and published.
